Pediatric Hematopoietic Stem Cell Transplant in the COVID-19 Pandemic: The Problems We Faced and The Strategies We Adopted

AUTHORS

Tahereh Rostami 1 , Seied Asadollah Mousavi 1 , Soroush Rad 1 , Azadeh Kiumarsi 1 , * , Amir Hesabi 1 , Mohammadreza Rostami 1 , Seied Amirhosein Mirhoseini 1 , Amirabbas Hedayatiasl 1

1 Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

How to Cite: Rostami T, Mousavi S A, Rad S, Kiumarsi A, Hesabi A, et al. Pediatric Hematopoietic Stem Cell Transplant in the COVID-19 Pandemic: The Problems We Faced and The Strategies We Adopted, Arch Pediatr Infect Dis. Online ahead of Print ; In Press(In Press):e104228. doi: 10.5812/pedinfect.104228.

ARTICLE INFORMATION

Archives of Pediatric Infectious Diseases: In Press (In Press); e104228
Published Online: September 1, 2020
Article Type: Discussion
Received: April 28, 2020
Revised: August 1, 2020
Accepted: August 5, 2020
Uncorrected Proof scheduled for 8 (4)
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Introduction: The COVID-19 pandemic has challenged hematopoietic stem cell transplant (HSCT) clinicians to profoundly re-organize their medical care to reduce complications without compromising patients’ inquiries. Since this pandemic is a foggy novel disease, scientific approved data are not available, and so decisions should be made based on expert opinions.

Methods: This is a pediatric HSCT center experience, including preventive and solving strategies specifically undertaken to address problems caused by the COVID-19 outbreak.

Results: In this report, we have shared our experience to alert healthcare professionals worldwide to get prepared accordingly.

Conclusion: We are not aware of the duration or outcome of the pandemic, but we are intended to learn from our experiences and figure out the best strategies to minimize the possible harms.

Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

1. Introduction

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as COVID-19, has become an unprecedented global pandemic. Iran reported its first confirmed cases of SARS-CoV-2 infection on 19 February 2020 (1), and since then, the infection rapidly surged to more than 140000 in three months and the mortality rate reached more than 7000 (2). In Tehran, the capital city, until 30 May 2020, more than 5000 confirmed cases have been reported (3).

Our pediatric hematopoietic stem cell transplant (HSCT) department, as the first and the most referred national center admitting different categories of pediatric patients needing HSCT, is embedded within a tertiary care hospital, affiliated to Tehran University of Medical Sciences (TUMS). As a referral center, our division provides HSCT for almost 100 pediatric patients per year, including high risk and complicated HSCTs from unrelated and haploidentical donors, and almost 70 patients per week receive outpatient visits in our pre- and post-HSCT clinics. Considering the central role of our HSCT unit, only a week after the announcement of the outbreak in the country, we had an expert session to modify the working guidelines and to develop new rules and regulations for HSCT recipients and donors to reduce the risk of infection in patients as well as staff. We considered national travel and accommodation restrictions, limitations in health care resources and in diagnostic and therapeutic modalities, the worries of patients’ families and caregivers, and also the concerns about the availability of post-HSCT prerequisites such as blood products, ICU care, and rehabilitation facilities. We took in to account the accessible published guidelines (4-6) from HSCT authorities around the world and modified them according to our circumstance as discussed below.

2. Arguments

2.1. The Plans We Made

We planned to disinfect the ward with 0.05% sodium hypochlorite (dilution 1:100), and for surfaces that may be damaged by sodium hypochlorite, ethanol-based products were used (at least 70%). We trained the staff about hand hygiene practices, social distance cautions, and wearing surgical masks while working in the unit. The employees were notified that if they happened to have symptoms related to COVID-19 (fever, cough, shortness of breath, anosmia) or to have close contact with a COVID-19 patient, they should leave the unit and be manage based on the national guideline of diagnosis and treatment of COVID-19. We restricted people’s commute into the unit and reduced non-essential staff & student contacts with inpatients.

In the pre-HSCT clinic, we planned to cancel most non-malignant indications for HSCTs except cases of transfusion-dependent acquired and inherited bone marrow failures, severe combined immunodeficiency (SCID), and osteopetrosis. We also planned to defer most of the low-risk malignant candidates for HSCT (7, 8), but we planned to continue the HSCT process for cases of neuroblastoma and acute leukemia. For patients who urgently needed HSCT and those with other criteria for HSCT, we planned to approach according to Figure 1.

Figure 1. HSCT candidate selection according to their COVID-19 status

Only one companion is allowed to stay with the respective patient during the treatment course, and s/he should be asymptomatic, and a negative COVID-19 PCR test should be presented before admission. No other visitor is allowed in the ward since the outbreak.

In the section for donor selection, as the operation room in our hospital is shared between different specialties, we planned not to use bone marrow harvesting as the source for providing stem cells due to the possibilities of donors’ exposure to COVID-19 while moving to the general operating room. Although the Food and Drug Administration (FDA) has reported that coronaviruses are not transfusion‐transmittable infections, we planned to select our donors according to Figure 2.

Figure 2. HSCT donor selection according to their COVID-19 status

In our post-HSCT clinic, the rooms’ windows were kept open for air ventilation, and only one companion at a time was allowed to enter the examination room with the patient. We planned to use virtual healthcare options by online medical platforms and teleconsultations, when safe and feasible. For those who came to the clinic, we indorsed to wear facial masks, keep at least one meter distance with others, and to wash their hands before entering and after exiting the clinic. The clinicians were also indulged to wear facial masks, disposable long-sleeved gown, and washing their hands before and after examining each patient.

We decided to treat patients presenting with post-transplant complications, out-patiently as much as possible, and to continue the follow-up appointments by phone (except when the physical examination would be necessary).

We organized to use triage from our emergency room (ER) division; if the patient presented with problems needing admission other than symptoms suggestive of COVID-19, we decided to check COVID-19 PCR and chest CT scan and if either were suggestive of COVID-19, the patient would be admitted in the general wards specialized for COVID-19 patients. If negative COVID-19 PCR and normal chest CT scan were obtained, then the patient would be admitted to our post-HSCT ward, where all patients and their helpers are obliged to wear surgery facial masks and are discouraged to leave the ward unless necessary.

2.2. Encountered Problems

When the COVID-19 outbreak was officially announced in Iran, we had eight patients admitted in our HSCT ward whose characteristics are summarized in Table 1. We continued their typical care but at the time of discharge, supplementary to their usual medications, according to initial positive data form multiple small studies (9-11), we administered hydroxychloroquine sulfate (pediatric dose: 6.5 mg/kg, not to exceed 400 mg) every 3 weeks until the pandemic lapse, as a prophylaxis for COVID-19. However, recent studies have questioned the role of the drug and highlighted its cardiotoxicity. Regarding that enough evidence are not available about the role of hydroxychloroquine in preventing COVID-19, we stopped its administration (12, 13). It worth mentioning that meanwhile, we did not observe any complication or adverse effect after its administration.

Table 1. Characteristics of Patients Who Were Admitted in our HSCT Ward Before the Announcement of the Outbreak
Underlying DiseaseSexAge, yDonorHSCT TypeDuration of Admission After HSCT, d
1OsteopetrosisMale2Full-matched auntAllogeneic22
2FAMale9Full -matched siblingAllogeneic24
3FAMale6Full -matched siblingAllogeneic23
4TMMale18Full -matched motherAllogeneic21
5ALLMale4Full -matched siblingAllogeneic16
6ALLMale18Full -matched siblingAllogeneic21
7SAAMale16Full -matched siblingAllogeneic40
8NeuroblastomaMale18-Autologous17

Abbreviations: ALL, acute lymphoblastic leukemia; FA, Fanconi anemia; SAA, severe aplastic anemia; TM, thalassemia major.

Unfortunately, due to international flight canceling and restrictions, we had no choice except to cancel the urgent HSCTs from unrelated foreign donors in a proportion of our patients, including seven cases of acute leukemia, a case of myelodysplastic syndrome (MDS) secondary to Fanconi anemia (FA), a transfusion-dependent FA, and a transfusion-dependent severe aplastic anemia (SAA). Even one of our Iranian donors refused to donate stem cells to a 9-year-old boy with acute lymphoblastic leukemia (ALL), due to the restrictions on traveling between cities and the phobia of infecting with COVID-19 during the hospital stay. These patients and their parents became very distressed, and we provided virtual counseling and mental-health assistance from our psychiatric team and assured them to be notified as soon as stem cell transferring became available. Since the onset of the COVID-19 epidemic, the number of patients admitted in the HSCT ward dropped substantially, and we only admitted thirteen patients for the last three months, whose data are summarized in Table 2. It is important to note that, as recommended in our guideline, we tested all the recipients, donors, and caregivers for COVID-19 PCR, and all test results were negative before admission. In the last three months, we have had 3 positive results of COVID-19 PCR in our center, but they were all in the adult age category and we did not come across any positive result in our pediatric patients.

Table 2. Characteristics of Patients Who Were Admitted in Our HSCT Ward After the Announcement of the Outbreak
Underlying DiseaseSexAge,DonorHSCT TypeDuration of ADmission After HSCT, d
1Pre B ALL in CR2Female7Full-matched siblingAllogeneic26
2AML in CR 1Female10HaploidenticalAllogeneic33
3Pre B ALL in CR2Male10HaploidenticalAllogeneic24
4Pre B ALL in CR2Female16Full-matched siblingAllogeneic22
5SAAMale13Full-matched motherAllogeneic20
6FAFemale8Full-matched siblingAllogeneic24
7AML in CR2Female10HaploidenticalAllogeneic44
8ALL in CR3Female14HaploidenticalAllogeneic17
9Neuroblastoma in CR2Male15-Autologous18
10Neuroblastoma in CR1Male4-Autologous14 (still admitted)
11Ph+ Pre B ALL in CR1Male16Full-matched siblingAllogeneic15 (still admitted)
12AML in CR1Female12Full-matched siblingAllogeneic7 (still admitted)
13Pre B ALL in CR2Male10Full-matched siblingAllogeneic4 (still admitted)

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CR, complete remission; FA, Fanconi anemia; SAA, severe aplastic anemia; TM, thalassemia major.

In the post-HSCT clinic, we faced three complicated patients needing admission; the first case was a 6-year-old boy with FA who had undergone HSCT from his HLA-matched sibling 41 days before and he presented with seizure. He did not have any respiratory symptoms, so was admitted to the ER, checked COVID-19 PCR, which came back negative, and then we admitted him in the post-HSCT ward. His brain MRI indicated evidence of posterior reversible encephalopathy syndrome (PRES), and so his cyclosporine, which was administered as GVHD prophylaxis was discontinued, and he was discharged after 2 days with a good condition.

The second case was a 14-year-old boy who had undergone haploidentical HSCT due to ALL in CR3, 65 days before, he presented with hemorrhagic cystitis, fever, and cough; COVID-19 PCR and chest CT scan plus infectious disease specialist consultation were requested while admitting in the ER. According to the radiologist report, his PCR result came back negative, and his chest CT scan was in favor of fungal infection. So he was admitted in post-HSCT ward, antifungal therapy, and bladder irrigation were administered, and he is still hospitalized due to the continuance of hemorrhagic cystitis complications. Worth mentioning, his pulmonary fungal infection is resolved.

The third case was a 16-years-old boy with thalassemia major who had undergone allogeneic HSCT from his HLA-matched mother, 70 days before. He presented with profuse watery diarrhea. Although the most possible diagnosis was gastrointestinal GVHD, COVID-19 PCR, and chest CT scan were requested, which results came back normal, and then he was admitted in the post-HSCT ward. He responded to corticosteroid therapy and was discharged with a good condition after 5 days.

3. Discussion

Limited data are available on the children who have been affected by COVID-19, so it is difficult to reach a reliable conclusion about the most susceptible pediatric population for SARS-CoV-2 infection and death. Inclusively, the data on COVID-19 in children is reassuring, infection rates have been reported to be lower than the general population, and most infected children have been asymptomatic and did not require invasive support (14). On the other hand, COVID-19 has imposed many challenges and constraints on patients undergoing HSCT. In patients who received the HSACT process, T- and B-lymphocytes and immune memory are lost, and mucocutaneous barriers are damaged. Thus, they are highly susceptible to opportunistic infections (15). Community-acquired viral respiratory infections can occur in more than half of HSCT recipients and so, CDC has recommended to strictly follow infection control measures, such as using protective gear and isolation (15, 16). Little is known about the effect of COVID-19 on pediatrics with HSCT. In a report from two cancer centers in New York, only two post-HSCT pediatric patients have reported being COVID-19 positive, and most of their patients have had mild disease, parallel to foregoing reports of pediatric patients from China and Europe (17).

4. Conclusions

Three months after the beginning of the outbreak, no evidence of COVID-19 has been detected in our pediatric HSCT ward so far. Unlike many centers who initially underestimated the risk of COVID-19 in pediatric patients, we promptly adopted preventive policies and strictly adhered to our plans. This has given us the proudness of being still successfully active in the field despite all the impediments and obstacles which came into our path due to the COVID-19 outbreak. We are now more powerful and experienced in dealing with future potential difficulties.

As a final point, we are not aware of the duration or outcome of the pandemic, but we know for sure that our vulnerable patients are being troubled, both directly and indirectly. So we are intended to learn from our experiences and figure out the best strategies to minimize the possible harms.

Acknowledgements

Footnotes

References

  • 1.

    Iran reports its first 2 cases of the new coronavirus. USA: New York Times; 2020.

  • 2.

    Iran coronavirus fatalities drop to double figures for first time in month. 2020. Available from: https://www.yjc.ir/en/news/45750/iran-coronavirus-fatalities-drop-to-double-figures-for-first-time-in-month.

  • 3.

    WHO. WHO and public health experts conclude COVID-19 mission to Islamic Republic of Iran. 2020. Available from: https://www.google.com/search?rlz=1C1GCEA_enIR898IR898&ei=5grSXumBPMORsAeT-r6oAg&q=tehran+covid&oq=tehran+covid.

  • 4.

    COVID-19 rapid guideline: hematopoietic stem cell transplantation NICE guideline. 2020, [cited 2020 Apr 01]. Available from: https://www.nice.org.uk/guidance/ng164.

  • 5.

    EMBT. 2020, [cited 2020 Mar 03]. Available from: https://www.ebmt.org/sites/default/files/2020-03/EBMT%20COVID19%20guidelines%20v.5.1%20%282020-03-30%29.pdf.

  • 6.

    Interim guidelines for COVID-19 management in hematopoietic cell transplant and cellular therapy patients Version 1.1. 2020, [cited 2020 Mar 09]. Available from: https://higherlogicdownload.s3.amazonaws.com/ASBMT/a1e2ac9a-36d2-4e23-945c-45118b667268/UploadedImages/COVID19Interim_Patient_Guidelines_3_9_20_V2.pdf.

  • 7.

    Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020. doi: 10.1038/s41409-020-0919-0. [PubMed: 32404975]. [PubMed Central: PMC7220575].

  • 8.

    Mousavi SA, Rad S, Rostami T, Vaezi M, Fumani HK, Babakhani D, et al. Guidance for facing dilemmas of hematopoietic stem cell transplant clinicians in the COVID-19 pandemic: an Iranian consensus. Mediterr J Hematol Infect Dis. 2020;12(1). e2020050. doi: 10.4084/MJHID.2020.050. [PubMed: 32670528]. [PubMed Central: PMC7340249].

  • 9.

    Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55(4):105945. doi: 10.1016/j.ijantimicag.2020.105945. [PubMed: 32194152]. [PubMed Central: PMC7156117].

  • 10.

    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. doi: 10.1038/s41422-020-0282-0. [PubMed: 32020029]. [PubMed Central: PMC7054408].

  • 11.

    Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. doi: 10.5582/bst.2020.01047. [PubMed: 32074550].

  • 12.

    Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020;173(4):287-96. doi: 10.7326/M20-2496. [PubMed: 32459529].

  • 13.

    Bajpai J, Pradhan A, Singh A, kant S. Hydroxychloroquine and COVID-19 – A narrative review. Indian J Tuberculosis. 2020. doi: 10.1016/j.ijtb.2020.06.004.

  • 14.

    Harwood R, Sinha I. Diagnosis of COVID-19 in children: the story evolves. BMC Med. 2020;18(1):158. doi: 10.1186/s12916-020-01631-9. [PubMed: 32460871]. [PubMed Central: PMC7254715].

  • 15.

    Centers for Disease Control Prevention; Infectious Disease Society of America; American Society of BMT. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1-125. CE1-7. [PubMed: 11718124].

  • 16.

    Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22(5):778-82. doi: 10.1093/clinids/22.5.778. [PubMed: 8722930].

  • 17.

    Gartrell-Corrado RD, Gampel B, Troullioud Lucas AG, Broglie L, Lee MT, Levine J, et al. COVID-19 in New York City pediatric hematology and oncology patients. SSRN Electron J. 2020. doi: 10.2139/ssrn.3582825.

  • COMMENTS

    LEAVE A COMMENT HERE: